Intestinal Dysbiosis, the Tryptophan Pathway and Nonalcoholic Steatohepatitis. (February 2022)

• Record Type: Journal Article
• Authors: Chen, Jiezhong; Vitetta, Luis; Henson, Jeremy D; Hall, Sean
• Is Part Of: International journal of tryptophan research. Volume 15(2022)
• Publication Date: 2022-02
• Subjects: Nonalcoholic steatohepatitis -- intestinal microbiome -- dysbiosis -- inflammation -- tryptophan; Biochemistry -- Periodicals; Tryptophan -- Periodicals; Tryptophan; Biochemical Phenomena; Biochemistry; Tryptophan; Electronic journals; Periodicals; Periodicals; 572.65
• DOI: 10.1177/11786469211070533
• Languages: English
• ISSNs: 1178-6469

Abstract

Non-alcoholic fatty liver disease (NAFLD) progresses from simple steatosis to steatohepatitis (NASH), which may then progress to the development of cirrhosis and hepatocarcinoma. NASH is characterized by both steatosis and inflammation. Control of inflammation in NASH is a key step for the prevention of disease progression to severe sequalae. Intestinal dysbiosis has been recognized to be an important causal factor in the pathogenesis of NASH, involving both the accumulation of lipids and aggravation of inflammation. The effects of gut dysbiosis are mediated by adverse shifts of various intestinal commensal bacterial genera and their associated metabolites such as butyrate, tryptophan, and bile acids. In this review, we focus on the roles of tryptophan and its metabolites in NASH in association with intestinal dysbiosis and discuss possible therapeutic implications.